MEGHANN DUNCAN: Open Payments
NPI 1902432578 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,776 in 92 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $653 · 2025 $1,776
Food & beverage: $1,659Education: $117
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 13 | $282 |
| Verona Pharma, Inc. | 10 | $215 |
| Regeneron Healthcare Solutions, Inc. | 20 | $214 |
| Insmed, Inc. | 13 | $207 |
| JAZZ PHARMACEUTICALS INC. | 6 | $179 |
| AstraZeneca Pharmaceuticals LP | 5 | $176 |
| GENZYME CORPORATION | 8 | $150 |
| Grifols USA, LLC | 3 | $68 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $47 |
| Electromed, Inc. | 2 | $43 |
Products named: DUPIXENT, Ohtuvayre, Arikayce, XYWAV, NUCALA, FASENRA, TRELEGY ELLIPTA, Prolastin-C Liquid.
Industry payments across TX — which companies pay providers there.
